Wall Street brokerages expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post $2.18 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $750,000.00 and the highest estimate coming in at $3.60 million. Tetraphase Pharmaceuticals reported sales of $11.58 million during the same quarter last year, which indicates a negative year over year growth rate of 81.2%. The firm is expected to report its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $10.05 million for the current fiscal year, with estimates ranging from $4.10 million to $16.57 million. For the next year, analysts expect that the company will post sales of $24.40 million, with estimates ranging from $10.50 million to $49.37 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.03. The company had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.93 million. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%.
Several research firms recently commented on TTPH. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. ValuEngine upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Gabelli lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 price target for the company. in a research report on Friday, March 15th. SunTrust Banks dropped their price target on Tetraphase Pharmaceuticals to $4.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Finally, Piper Jaffray Companies dropped their price target on Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, March 15th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $4.08.
Several large investors have recently made changes to their positions in the business. Paloma Partners Management Co purchased a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $33,000. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% during the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 15,000 shares during the period. SG Americas Securities LLC purchased a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $69,000. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 21,089 shares during the period. Finally, State of Wisconsin Investment Board boosted its position in shares of Tetraphase Pharmaceuticals by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 71,000 shares of the biopharmaceutical company’s stock valued at $95,000 after buying an additional 16,300 shares during the period. Institutional investors and hedge funds own 39.56% of the company’s stock.
TTPH traded down $0.04 on Thursday, hitting $0.78. The company had a trading volume of 366,100 shares, compared to its average volume of 608,891. The firm has a market cap of $43.25 million, a P/E ratio of -0.57 and a beta of 2.85. Tetraphase Pharmaceuticals has a 12-month low of $0.75 and a 12-month high of $4.49. The company has a current ratio of 7.28, a quick ratio of 7.10 and a debt-to-equity ratio of 0.53.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Further Reading: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.